Talk:Cabergoline: Difference between revisions

Line 1:

{{headerpanel|{{Stub}}}}

[[File:Cabergoline.svg|300px|thumbnail|The structure of cabergoline]]

'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a derivative of [[LSD]] or more specifically [[AL-LAD]] ~~and~~ shares many effects with related, non-psychedelic compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.

'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], or more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.

Cabergoline is not predominantly psychedelic, it exerts its effects at the [[dopamine]] D2 receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT2A receptor where it acts as a partial agonist.

Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D2 receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT2A receptor where it acts as a partial agonist.

Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.</ref><ref>Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.</ref>

@@ Line 1: / Line 1: @@
 {{headerpanel|{{Stub}}}}
 [[File:Cabergoline.svg|300px|thumbnail|The structure of cabergoline]]
-'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a derivative of [[LSD]] or more specifically [[AL-LAD]] and shares many effects with related, non-psychedelic compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
+'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], or more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
-Cabergoline is not predominantly psychedelic, it exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist.
+Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist.
 Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.</ref><ref>Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.</ref>